September 17, 2006. The U.S. Food and Drug Administration (FDA) has the responsibility to determine if newly developed medical products are safe and effective.
Read More »On Health Policy
Letter to the Senate HELP Committee on Enhancing Drug Safety and Innovation Act
September 28, 2006. NCHR was disappointed to hear that the Senate is considering marking up S. 3807 “The Enhancing Drug Safety and Innovation Act” before holding a hearing.
Read More »Invited Testimony Before the Standing Committee on Health, Canadian Parliament, Ottawa
June 8, 2006. Clinical trials are a major source of information on the short-term risks of silicone breast implants. In clinical trials, the goal is to follow women prospectively to determine what complications and health problems occur, and to compare that to a control group.
Read More »NCHR Statement on Protecting Patients from Long-Term Risks
February 17, 2005. When Americans take medication, they don’t expect to have to read the studies that have been conducted on the product.
Read More »NCHR Testimony to FDA Regarding Suicide and the Use of Antidepressants by Children
September 13, 2004. The widespread use of antidepressant drugs by children and youth in the United States is cause for great concern.
Read More »